DiaMedica Therapeutics Announces That The FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Portfolio Pulse from Happy Mohamed
DiaMedica Therapeutics (NASDAQ:DMAC) announced that the FDA has removed the clinical hold on its ReMEDy2 phase 2/3 trial for DM199 in the treatment of acute ischemic stroke (AIS). The trial is set to resume as soon as possible, with the potential to serve as a pivotal registration study of DM199 in this patient population.
June 21, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA lifts clinical hold on DiaMedica's ReMEDy2 phase 2/3 trial for DM199 in acute ischemic stroke treatment, allowing the trial to resume.
The FDA lifting the clinical hold on DiaMedica's ReMEDy2 phase 2/3 trial for DM199 is a positive development for the company. This allows the trial to resume, potentially leading to the approval and commercialization of DM199 for AIS treatment. This news is likely to have a positive short-term impact on DMAC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100